Alendronate is more effective than elcatonin in improving pain and quality of life in postmenopausal women with osteoporosis

Osteoporosis International

Volumn 22, Issue 10, 2011, Pages 2735-2742

  Iwamoto, J ^a,b   Makita, K ^a   Sato, Y ^c   Takeda, T ^a   Matsumoto, H ^a  

^a KEIO UNIVERSITY   (Japan)

^b Keiyu Orthopaedic Hospital   (Japan)

^c Mitate Hospital   (Japan)

Author keywords

Alendronate; Back pain; Elcatonin; Osteoporosis; Postmenopausal women

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; ELCATONIN;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BACKACHE; BONE TURNOVER; DRUG EFFECT; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SHORT FORM 8;

AGED; AGED, 80 AND OVER; ALENDRONATE; ALKALINE PHOSPHATASE; BACK PAIN; CALCITONIN; COLLAGEN TYPE I; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PAIN MEASUREMENT; PEPTIDES; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 80755143291     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-010-1495-8     Document Type: Article

References (48)

1. Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Mönkkönen J, Auriola S, Chilton KM, Russell RG (1999) Molecular mechanism of action of bisphosphonate. Bone 24(5 Suppl):73S-79S
2. Iwamoto J, Takeda T, Sato Y (2006) Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. Curr Med Res Opin 22:919-928
3. Iwamoto J, Takeda T, Sato Y (2007) Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis-usefulness of alendronate and risedronate. Expert Opin Pharmacother 8:2743-2756
4. Iwamoto J, Sato Y, Takeda T, Matsumoto H (2008) Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature. Clin Interv Aging 3:483-489
5. Morikawa T, Munekata E, Sakakibara S, Noda T, Otani M (1976) Synthesis of eel-calcitonin and (asu1, 7)-eel-calcitonin: contribution of the disulfide bond to the hormonal activity. Experientia 32:1104-1106
6. Otani M, Kitazawa S, Yamaguchi H, Meguro T, Orimo H (1978) Biological activity of (asu1, 7)-eel-calcitonin. Clin Med 20:2217-2222 (in Japanese)
7. Orimo H (1990) The development of a novel therapy for bone disease, the discoveryof elcatonin. In: Christiansen C, Overgard K (eds) Osteoporosis 1990. Handelstrykkeriet, Aalborg, pp 2091-2095
8. Yamamoto I, Morita R, Fukunaga M, Dokoh S, Shigeno C, Torizuka K, Noda T (1981) Adenylate cyclase activation and competitive binding with renal tissue using synthetic eel calcitonin analog and its fragments. Endocrinology 108:698-702
9. Asahi-Kasei (2003) Outline of the results of a clinical trial of intramuscular elcatonin 20 S. http://www.asahi-kasei.co.jp/asahi/jp/news/2003/ pdf/me030606 (in Japanese)
10. Yoh K, Tanaka K, Ishikawa A, Ishibashi T, Uchino Y, Sato Y, Tobinaga M, Hasegawa N, Kamae S, Yoshizawa M (2005) Health-related quality of life (HRQOL) in Japanese osteoporotic patients and its improvement by elcatonin treatment. J Bone Miner Metab 23:167-173
11. Nevitt MC, Thompson DE, Black DM, Rubin SR, Ensrud K, Yates AJ, Cummings SR (2000) Effect of alendronate on limitedactivity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture intervention trial research group. Arch Intern Med 160:77-85
12. Miller PD, Shergy WJ, Body JJ, Chen P, Rohe ME, Krege JH (2005) Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate. J Rheumatol 32:1556-1562
13. Iwamoto J, Takeda T, Ichimura S, Matsu K, Uzawa M (2003) Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis. J Orthop Sci 8:532-537
14. Iwamoto J, Takeda T, Ichimura S, Uzawa M (2003) Comparative effects of treatment with etidronate and alendronate on bone resorption, back pain, and activities of daily living in elderly women with vertebral fractures. Keio J Med 52:230-235
15. Iwamoto J, Takeda T, Sato Y, Uzawa M (2004) Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption, and chronic back pain in postmenopausal women with osteoporosis. Clin Rheumatol 23:383-389
16. Iwamoto J, Takeda T, Sato Y, Uzawa M (2005) Effect of wholebody vibration exercise on lumbar bone mineral density, bone turnover, and chronic back pain in post-menopausal osteoporotic women treated with alendronate. Aging Clin Exp Res 17:157-163
17. Ohtori S, Akazawa T, Murata Y, Kinoshita T, Yamashita M, Nakagawa K, Inoue G, Nakamura J, Orita S, Ochiai N, Kishida S, Takaso M, Eguchi Y, Yamauchi K, Suzuki M, Aoki Y, Takahashi K (2010) Risedronate decreases bone resorption and improves low back pain in postmenopausal osteoporosis patients without vertebral fractures. J Clin Neurosci 17:209-213
18. Kawate H, Ohnaka K, Adachi M, Kono S, Ikematsu H, Matsuo H, Higuchi K, Takayama T, Takayanagi R (2010) Alendronate improves QOL of postmenopausal women with osteoporosis. Clin Interv Aging 5:123-131
19. Orimo H, Sugioka Y, Fukunaga M, Muto Y, Hotokebuchi T, Gorai I, Nakamura T, Kushida K, Tanaka H, Ikai T, Oh-hashi Y (1998) Diagnostic criteria of primaryosteoporosis. J Bone Miner Metab 16:139-150
20. Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-Hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H (2001) Diagnostic criteria for primaryosteoporosis: year 2000 revision. J Bone Miner Metab 19:331-337
21. Uchida S, Taniguchi T, Shimizu T, Kakikawa T, Okuyama K, Okaniwa M, Arizono H, Nagata K, Santora AC, Shiraki M, Fukunaga M, Tomomitsu T, Ohashi Y, Nakamura T (2005) Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study. J Bone Miner Metab 23:382-388
22. Orimo H, Morii H, Inoue T, Yamamoto K, Minaguchi H, Ishii Y, Morita K, Fujimaki E, Watanabe R, Harada S, Honjo H, Fujita T (1996) Effect of elcatonin on involutional osteoporosis. J Bone Miner Metab 14:73-78
23. Lorish CD, Maisiak R (1986) The face scale: a brief, nonverbal method for assessing patient mood. Arthritis Rheum 29:906-909
24. Nishizawa Y, Nakamura T, Ohta H, Kushida K, Gorai I, Shiraki M, Fukunaga M, Hosoi T, Miki T, Chaki O, Ichimura S, Nakatsuka K, Miura M, Committee on the Guidelines for the Use of Biochemical Markers of Bone Turnover in Osteoporosis Japan Osteoporosis Society (2004) Guidelines for the use of biochemical markers of bone turnover in osteoporosis. J Bone Miner Metab 23:97-104
25. Shibata K, Takeda M, Ito A, Sagai H (1998) Ovariectomy-induced hyperalgesia and antinociceptive effect of elcatonin, a synthetic eel calcitonin. Pharmacol Biochem Behav 60:371-376
26. Martin MI, Goicoechea C, Ormazabal MJ, Lopez F, Alfaro MJ (1995) Analgesic effect of two calcitonins and in vitro interaction with opioids. Gen Pharmacol 26:641-647
27. Iwamoto J, Takeda T, Sato Y, Uzawa M (2004) Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis. Yonsei Med J 45:676-682
28. Iwamoto J, Takeda T, Sato Y, Uzawa M (2005) Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis. Yonsei Med J 46:750-758
29. Iwamoto J, Takeda T, Sato Y, Uzawa M (2005) Early changes in urinarycross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis. J Bone Miner Metab 23:238-242
30. Iwamoto J, Takeda T, Sato Y, Uzawa M (2007) Comparison of the effect of alendronate on lumbar bone mineral density and bone turnover in men and postmenopausal women with osteoporosis. Clin Rheumatol 26:161-167
31. Iwamoto J, Sato Y, Uzawa M, Takeda T, Matsumoto H (2008) Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis. Yonsei Med J 49:119-128
32. Kushida K, Shiraki M, Nakamura T, Kishimoto H, Morii H, Yamamoto K, Kaneda K, Fukunaga M, Inoue T, Nakashima M, Orimo H (2002) The efficacy of alendronate in reducing the risk of vertebral fracture in Japanese patients with osteoporosis: a randomized, double-blind, active-controlled, double-dummy trial. Curr Ther Res Clin Exp 63:606-620
33. Agarwala S, Sule A, Pai BU, Joshi VR (2002) Alendronate in the treatment of avascular necrosis of the hip. Rheumatology (Oxford) 41:346-347
34. Gangji V, Appelboom T (1999) Analgesic effect of intravenous pamidronate on chronic back pain due to osteoporotic vertebral fractures. Clin Rheumatol 18:266-267
35. Glover D, Lipton A, Keller A, Miller AA, Browning S, Fram RJ, George S, Zelenakas K, Macerata RS, Seaman JJ (1994) Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. Cancer 74:2949-2955
36. Gonzalez E, Pavia C, Ros J, Villaronga M, Valls C, Escola J (2001) Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 14:529-533
37. Hortobagyi GN, Terhiault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 335:1785-1791
38. Siris ES, Chines AA, Altman RD, Brown JP, Johnston CC Jr, Lang R, McClung MR, Mallette LE, Miller PD, Ryan WG, Singer FR, Tucci JR, Eusebio RA, Bekker PJ (1998) Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study. J Bone Miner Res 13:1032-1038
39. Brown MF, Hukkanen MV, McCarthy ID, Redfern DR, Batten JJ, Crock HV, Hughes SP, Polak JM (1997) Sensoryand sympathetic innervation of the vertebral endplate in patients with degenerative disc disease. J Bone Joint Surg Br 79:147-153
40. Hartman JM, Berger A, Baker K, Bolle J, Handel D, Mannes A, Pereira D, St Germain D, Ronsaville D, Sonbolian N, Torvik S, Calis KA, Phillips TM, Cizza G, Premenopausal, Osteoporosis, Women, Alendronate, Depression (P. O. W. E. R.) Study Group (2006) Quality of life and pain in premenopausal women with major depressive disorder: the POWER study. Health Qual Life Outcomes 4:2
41. Ohtori S, Inoue G, Koshi T, Ito T, Watanabe T, Yamashita M, Yamauchi K, Suzuki M, Doya H, Moriya H, Takahashi Y, Takahashi K (2007) Sensoryinnervation of lumbar vertebral bodies in rats. Spine 32:1498-1502, Philadelphia, PA
42. Ohtori S, Inoue G, Koshi T, Ito T, Yamashita M, Yamauchi K, Suzuki M, Doya H, Moriya H, Takahashi Y, Takahashi K (2007) Characteristics of sensorydorsal root ganglia neurons innervating the lumbar vertebral body in rats. J Pain 8:483-488
43. Bianchi M, Franchi S, Ferrario P, Sotgiu ML, Sacerdote P (2008) Effects of the bisphosphonate ibandronate on hyperalgesia, substance P, and cytokine levels in a rat model of persistent inflammatorypain. Eur J Pain 12:284-292
44. Orita S, Ohtori S, Koshi T, Yamashita M, Yamauchi K, Inoue G, Suzuki M, Eguchi Y, Kamoda H, Arai G, Ishikawa T, Miyagi M, Ochiai N, Kishida S, Takaso M, Aoki Y, Toyone T, Takahashi K (2010) The effects of risedronate and exercise on osteoporotic lumbar rat vertebrae and their sensoryinnervation. Spine 35:1974-1982
45. Wagner R, Myers RR (1996) Schwann cells produce tumor necrosis factor alpha: expression in injured and non-injured nerves. Neuroscience 73:625-629
46. Wagner R, Myers RR (1996) Endoneurial injection of TNF-alpha produces neuropathic pain behaviors. NeuroReport 7:2897-2901
47. Matsumoto T, Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Morii H, Ohashi Y, Nakamura T (2009) Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int 20:1429-1437
48. Fujiwara S, Kasagi F, Masunari N, Naito K, Suzuki G, Fukunaga M (2003) Fracture prediction from bone mineral density in Japanese men and women. J Bone Miner Res 18:1547-1553